Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access
Status:
Completed
Trial end date:
2017-10-23
Target enrollment:
Participant gender:
Summary
The Objectives of this study are:
1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional
maturation when administered during the maturation process compared with placebo.
2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary
procedures to aid in fistula maturation compared with placebo.
3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for
hemodialysis compared with placebo.
This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be
conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will
be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health
Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The
investigators expect to enroll 128 patients. Patients will be assigned to treatment groups
with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation.
Patients will be stratified based on fistula location (lower arm versus upper arm).